Skin Cancer
Regeneron R2810-ONC-1788
Official Title: A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Study Purpose: To determine if cemiplimab will prevent CSCC from returning after surgery and radiation. The researchers also want to find out if cemiplimab will help people live longer, how study participation affects how people feel, and side effects that people may experience during the study.
Status:
Recruiting